Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6JLNT)

Drug Name

177-Lu-NeoB Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Gastrin-releasing peptide receptor (GRPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-7147	DMGDF2X	Irritable bowel syndrome	DD91.0	Phase 2	[3]
RC-3095	DMIG98L	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
177Lu-labelled NeoBOMB1	DM2TSMD	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
177Lu-AMBA	DMFG1YA	Breast cancer	2C60-2C65	Phase 1	[5]
BIM-26226	DM9F4LP	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[6]
kuwanon H	DMVQDNR	Discovery agent	N.A.	Investigative	[7]
bombesin	DMDFQ0Y	Discovery agent	N.A.	Investigative	[8]
PD 168368	DMFNQEA	Discovery agent	N.A.	Investigative	[9]
MK-5046	DMS7C6R	Discovery agent	N.A.	Investigative	[10]
bantag-1	DM4OT8M	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastrin-releasing peptide receptor (GRPR)	TTC1MVT	GRPR_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03872778) [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay). U.S. National Institutes of Health.
2	68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299.
3	Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
4	Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262-8.
5	Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010 Oct;30(10):4039-48.
6	Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86.
7	Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9.
8	Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
9	Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11.
10	Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.